×
About 42,685 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  12,645 results

Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A...
https://doi.org/10.1371/journal.pone.0278578
PloS One; Hao Q, Foroutan F et. al.

Dec 6th, 2022 - The prognostic value of age and other non-hematological factors in predicting outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) undergoing antileukemic therapy is not well understood. We performed a systematic review to ...

A retrospective study of cladribine and low-dose cytarabine-based regimens for the trea...
https://doi.org/10.1002/cncr.34564
Cancer Bazinet A, Darbaniyan F et. al.

Dec 3rd, 2022 - Patients with higher risk chronic myelomonocytic leukemia (CMML) have limited therapeutic options beyond hydroxyurea and hypomethylating agents (HMAs). Regimens based on a backbone of cladribine (CLAD), low-dose cytarabine (LDAC), and an HMA are e...

Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted trea...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716776
Journal of Hematology & Oncology; Bäumer N, Scheller A et. al.

Dec 3rd, 2022 - Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognosis of about 30%. Therefore, the develo...

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloabla...
https://doi.org/10.1038/s41409-022-01882-5
Bone Marrow Transplantation; Swoboda R, Labopin M et. al.

Dec 3rd, 2022 - Cyclophosphamide is frequently substituted with fludarabine (Flu) in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) ver...

DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer.
https://doi.org/10.1073/pnas.2216712119
Proceedings of the National Academy of Sciences of the Un... Zhang J, Huang J et. al.

Dec 3rd, 2022 - SF3B1 is the most frequently mutated spliceosomal gene in cancer. Several hotspot mutations are known to disrupt the interaction of SF3B1 with another splicing factor, SUGP1, resulting in the RNA missplicing that characterizes mutant SF3B1 cancers...

see more →

Guidelines  12 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  32 results see all →

Clinicaltrials.gov  1,717 results

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04774393

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability and recommended phase 2 dose (RP2D) of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with either ivosidenib (Arm A) or enasidenib (Arm B) for patients with acute...

Longitudinal Studies of Patient With FPDMM
https://clinicaltrials.gov/ct2/show/NCT03854318

Oct 14th, 2022 - Germline mutations in RUNX1 are responsible for familial platelet disorder with associated myeloid malignancies (FPDMM, or simply FPD), an autosomal dominant disease characterized by defective megakaryocytic development, low platelet counts, prolo...

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02675452

Oct 14th, 2022 - This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloi...

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
https://clinicaltrials.gov/ct2/show/NCT02421939

Oct 14th, 2022 - Participants considered an adult according to local regulations at the time of signing informed consent may participate in this study. Participants will be randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will ent...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Oct 14th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

see more →

News  2,654 results

ASH 2022: New Clinical Data Challenge Long-held Assumptions
https://www.medscape.com/viewarticle/984997

Dec 5th, 2022 - NEW ORLEANS — In addition to news on the latest in clinical care and drug development, some eyebrow-raising findings that challenge long-held but untested assumptions are promised from the annual meeting of the American Society of Hematology. The ...

New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia
https://www.medpagetoday.com/hematologyoncology/leukemia/102019

Dec 2nd, 2022 - The FDA approved the IDH1 inhibitor olutasidenib (Rezlidhia) for relapsed or refractory acute myeloid leukemia (AML). The approved indication stipulates use of olutasidenib in relapsed/refractory AML associated with an IDH1 mutation. The FDA also ...

FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
https://www.medscape.com/viewarticle/984907

Dec 2nd, 2022 - The US Food and Drug Administration (FDA) has approved olutasidenib (Rezlidhia) for use in certain patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Specifically, the drug is approved for use in patients who have R/R AML wit...

Neurologic Symptoms Linked With Death in Pediatric Leukemia
https://www.medscape.com/viewarticle/984925

Dec 2nd, 2022 - Neurologic manifestations such as headache, neuropathy, seizures, and cell infiltration are common in pediatric patients with acute leukemia and are associated with a higher mortality rate, according to a retrospective, analytic, longitudinal stud...

Novel Treatments Begin to Rival Transplant in AML and DLBCL
https://www.onclive.com/view/novel-treatments-begin-to-rival-transplant-in-aml-and-dlbcl

Nov 21st, 2022 - The fields of diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) are quickly expanding to accommodate novel therapies such as polatuzumab vedotin-piiq (Polivy) plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vi...

see more →

Patient Education  14 results see all →